SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Szucs, T. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szucs, T. D
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The growing healthcare burden of CHF

Thomas D Szucs

University Hospital, Zurich, Switzerland, thomas.szucs{at}vdi.usz.ch

Despite advances in treatment, congestive heart failure (CHF) remains a major burden on healthcare budgets throughout the western world. Two main factors in the increasing incidence of CHF are the shift in the age distribution of the population and, paradoxically, an improvement in the management of other conditions, such as myocardial infarction. This increases the number of patients surviving acute cardiovascular events who proceed to develop CHF. Certain sub-populations of patients consume most of the healthcare resources devoted to CHF management, with some 90% of resources utilised by patients in NYHA classes III or IV, and hospitalisation accounting for 60 to 75% of overall costs.

Management strategies aimed at reducing both disease severity and the need for hospitalisation are therefore likely to be most effective in reducing the economic burden of CHF on healthcare systems.

Key Words: pharmaco-economics • cardiovascular disease • CHF

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 1 suppl, 2-6 (2000)
DOI: 10.3317/jraas.2000.029


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
CirculationHome page
N. Dib, R. E. Michler, F. D. Pagani, S. Wright, D. J. Kereiakes, R. Lengerich, P. Binkley, D. Buchele, I. Anand, C. Swingen, et al.
Safety and Feasibility of Autologous Myoblast Transplantation in Patients With Ischemic Cardiomyopathy: Four-Year Follow-Up
Circulation, September 20, 2005; 112(12): 1748 - 1755.
[Abstract] [Full Text] [PDF]



Advertisement